AZ's Lynparza Shines Again In Prostate Cancer Study

PARP Inhibitor Improves Overall Survival

 
• By Kevin Grogan
  
Jigsaw_Pieces
If approved, prostate cancer would be the fourth indication for Lynparza • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category